Immunogen Inc
IMGN
IMGN was delisted on the 9th of February, 2024.
204 hedge funds and large institutions have $1B invested in Immunogen Inc in 2022 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 69 increasing their positions, 68 reducing their positions, and 44 closing their positions.
98% more call options, than puts
Call options by funds: $6.78M | Put options by funds: $3.42M
6% more capital invested
Capital invested by funds: $948M → $1B (+$55.2M)
1% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 68
8% less funds holding
Funds holding: 222 → 204 (-18)
39% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$27.3M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
+$18M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$17.5M |
| 4 |
Jennison Associates
New York
|
+$16M |
| 5 |
State Street
Boston,
Massachusetts
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$40M |
| 2 |
ClearBridge Investments
New York
|
-$23.1M |
| 3 |
Renaissance Technologies
New York
|
-$8.15M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$7.67M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.76M |
IMGN Hedge Fund Activity: Q4 2022 in Review
204 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q4 2022, worth a combined $1B — up 5.8% from $948M a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of IMGN and 27 opened new positions — a net loss of 17 holders — while 68 trimmed existing stakes and 69 added.
The largest buyer was Woodline Partners, opening a new position worth an estimated $27.3M. The largest seller was Deerfield Management, cutting an estimated $40M.
- 204 institutional investors held Immunogen Inc (IMGN) as of Q4 2022, down from 222 in Q3 2022.
- Funds reported $1B of Immunogen Inc stock for Q4 2022, up 5.8% quarter-over-quarter.
- 27 funds opened new Immunogen Inc positions in Q4 2022 and 44 closed out, a net change of -17 holders.
- The largest Immunogen Inc buyer in Q4 2022 was Woodline Partners, an estimated $27.3M added.
- The largest Immunogen Inc seller in Q4 2022 was Deerfield Management, an estimated $40M sold.
Based on aggregated 13F filings for Q4 2022.